DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy
Figure 4
SYC-522 promoted the differentiation of MLL-rearranged leukemia cell lines and primary MLL-rearranged AML cells.
(A) MV4-11 cells were treated with 3 µM SYC-522 and MOLM13 cells were treated with 10 µM SYC-522 for up to 18 days. Cells were analyzed by flow cytometry for CD14 expression. MFI (mean fluorescence intensity) ratio = MFI (SYC-522 treated)/MFI (untreated), n = 3 independent experiments, *p<0.05, unpaired t-test; (B) Primary MLL-rearranged AML cells were harvested after clonogenic assays and stained with Wright Giemsa (original magnification 40X).